Physician profile
Xiaowen Wang
NPI 1548371180
$33,228.63
in general payments reported to CMS, 2019-2025
20 companies · $7,510 in 2025
The $7,510 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $4,450 · 2021: $4,581 · 2022: $576 · 2023: $10K · 2024: $5,524 · 2025: $7,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Travel and Lodging: $2,610 · Food and Beverage: $2,003 · Long Term Medical Supply Or Device Loan: $598 · Honoraria: $360 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,798.75 |
| Travel and Lodging | $2,609.78 |
| Food and Beverage | $2,003.47 |
| Long Term Medical Supply Or Device Loan | $598.20 |
| Honoraria | $360.00 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $9,405.89 | 2023 | Tukysa |
| Stemline Therapeutics INC. | $6,889.60 | 2022-2025 | Orserdu |
| Glaxosmithkline, LLC. | $3,600.00 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $2,865.86 | 2022-2025 | Lynparza |
| Novartis Pharmaceuticals Corporation | $2,499.40 | 2021-2025 | |
| Genzyme Corporation | $1,905.00 | 2021 | |
| Kite Pharma, INC. | $1,724.42 | 2020-2021 | |
| Daiichi Sankyo INC. | $1,123.85 | 2022-2025 | Enhertu, Enhertu |
| Gilead Sciences, INC. | $910.39 | 2021-2024 | Trodelvy |
| Immunomedics, INC. | $800.00 | 2020 | |
| Lilly USA, LLC | $755.60 | 2019-2025 | Verzenio |
| Ge Healthcare | $140.45 | 2022 | |
| Genentech, INC. | $132.13 | 2025 | Itovebi |
| Puma Biotechnology, INC. | $122.83 | 2019 | |
| Eisai INC. | $118.15 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $112.17 | 2024 | Auvelity |
| Celgene Corporation | $44.36 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $35.51 | 2019 | |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | Keytruda |
| Astellas Pharma US INC | $17.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaowen Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.